

MULTIVALENT T CELL RECEPTOR COMPLEXES

General Background of the Invention

Field of the Invention

The invention relates to T cell receptors (TCRs) in multivalent form and
5 to their use in detecting cells which carry specific peptide antigens presented
in the context of major histocompatibility complex (MHC) at their surface. The
invention further relates to delivery methods, in particular for the delivery of
therapeutic agents, to target cells using the multimeric TCRs.

Description of the Related Art

10 1. Antigen presentation on the cell surface

MHC molecules are specialised protein complexes which present short
protein fragments, peptide antigens, for recognition on the cell surface by the
cellular arm of the adaptive immune system.

Class I MHC is a dimeric protein complex consisting of a variable heavy chain
15 and a constant light chain, β 2microglobulin. Class I MHC presents peptides
which are processed intracellularly, loaded into a binding cleft in the MHC,
and transported to the cell surface where the complex is anchored in the
membrane by the MHC heavy chain. Peptides are usually 8-11 amino acids
in length, depending on the degree of arching introduced in the peptide when
20 bound in the MHC. The binding cleft which is formed by the membrane distal
 α 1 and α 2 domains of the MHC heavy chain has "closed" ends, imposing quite
tight restrictions on the length of peptide which can be bound.

Class II MHC is also a dimeric protein consisting of an α (heavy) and β (light)
chain, both of which are variable glycoproteins and are anchored in the cell by
25 transmembrane domains. Like Class I MHC, the Class II molecule forms a
binding cleft in which longer peptides of 12-24 amino acids are inserted.

R f r n c s:

- Ahmad, I., and Allen, T. M. (1992).** *Cancer Res* 52, 4817-20.
- Ahmad, I., Longenecker, et al. (1993).** *Cancer Res* 53, 1484-8
- Alifantis, I., O. Azogui, et al. (1998).** *Immunity* 9(5): 649-55.
- 5 **Allen, T. M. (1997).** *Drugs* 54 Suppl 4, 8-14.
- Allen, T. M. (1994).** *Trends Pharmacol Sci* 15,215-20.
- Allen, T. M., Ahmad, et al. (1995).** *Biochem Soc Trans* 23, 1073-9.
- Allen, T. M., Brandeis, E., et al. (1995).** [published erratum appears in
Biochim Biophys Acta 1995 Dec 13;1240(2):285]. *Biochim Biophys Acta*
10 1237,99-108.
- Allen, T. M., Newman, et al. (1995).** *Int J Cancer* 62,199-204.
- Altamirano, M. M., C. Garcia, et al. (1999).** *Nature Biotechnology* 17: 187-191.
- Altamirano, M. M., R. Golbik, et al. (1997).** *Proc Natl Acad Sci U S A* 94(8):
15 3576-8.
- Altman, J. D., Moss, P. A. H., et al. (1996).** *Science* 274, 94-6.
- Amati, B., S. Dalton, et al. (1992).** *Nature* 359(6394): 423-6.
- Bangham, A. D., Standish, M. M., et al. (1965).** *J Mol Biol* 13, 238-52.
- Barenholz, Y., Amselem, S., et al. (1979).** *FEBS Lett* 99, 210-4.
- 20 **Barker, D. F., and Campbell, A. M. (1981).** *J Mol Biol* 146, 451-67.
- Barker, D. F., and Campbell, A. M. (1981).** *J Mol Biol* 146, 469-92.
- Bentley, G. A., Boulot, G., et al. (1995).** *Science* 267, 1984-7 Issn: 0036-8075.
- Bjorkman, P. J., Strominger, J. L., et al. (1985)** *J. Mol. Biol* 186(1) 205-10.
25 Issn: 0022-2836.

R f r e n c e s:

- Ahmad, I., and Allen, T. M. (1992).** *Cancer Res* 52, 4817-20.
- Ahmad, I., Longenecker, et al. (1993).** *Cancer Res* 53, 1484-8
- Alifantis, I., O. Azogui, et al. (1998).** *Immunity* 9(5): 649-55.
- 5 **Allen, T. M. (1997).** *Drugs* 54 *Suppl* 4, 8-14.
- Allen, T. M. (1994).** *Trends Pharmacol Sci* 15,215-20.
- Allen, T. M., Ahmad, et al. (1995).** *Biochem Soc Trans* 23, 1073-9.
- Allen, T. M., Brandeis, E., et al. (1995).** [published erratum appears in
Biochim Biophys Acta 1995 Dec 13;1240(2):285]. *Biochim Biophys Acta*
10 1237,99-108.
- Allen, T. M., Newman, et al. (1995).** *Int J Cancer* 62,199-204.
- Altamirano, M. M., C. Garcia, et al. (1999).** *Nature Biotechnology* 17: 187-191.
- Altamirano, M. M., R. Golbik, et al. (1997).** *Proc Natl Acad Sci U S A* 94(8):
15 3576-8.
- Altman, J. D., Moss, P. A. H., et al. (1996).** *Science* 274, 94-6.
- Amati, B., S. Dalton, et al. (1992).** *Nature* 359(6394): 423-6.
- Bangham, A. D., Standish, M. M., et al. (1965).** *J Mol Biol* 13, 238-52.
- Barenholz, Y., Amselem, S., et al. (1979).** *FEBS Lett* 99, 210-4.
- 20 **Barker, D. F., and Campbell, A. M. (1981).** *J Mol Biol* 146, 451-67.
- Barker, D. F., and Campbell, A. M. (1981).** *J Mol Biol* 146, 469-92.
- Bentley, G. A., Boulot, G., et al. (1995).** *Science* 267, 1984-7 Issn: 0036-8075.
- Bjorkman, P. J., Strominger, J. L., et al. (1985)** *J. Mol. Biol* 186(1) 205-10.
25 Issn: 0022-2836.

marked up copy of spec.

105

Image number : Boston 975805975821v21

5

1

Document comparison done by DeltaView on Friday, July 25, 2003 15:27:35

Input:	
Document 1	iManage://BOSDOCS/Boston/975805/2
Document 2	iManage://BOSDOCS/Boston/975821/1
Rendering set	Hale and Dorr Standard

Legend:	
<u>Insertion</u>	
<u>Deletion</u>	
<u>Moved from</u>	
<u>Moved to</u>	
Format change	
Moved deletion	
Inserted cell	
Deleted cell	
Moved cell	
Split/Merged cell	
Padding cell	

Statistics:	
	Count
Insertions	128
Deletions	74
Moved from	145
Moved to	145
Format changed	0
Total changes	492